Effect of vitamin D supplementation in treatment of diabetic hemodialysis patients

The effects of vitamin D supplementation compared with the placebo on gene expression related to insulin and lipid in diabetic hemodialysis patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180525039828N1

Enrollment

Registered

2018-08-15

Start date

2018-01-14

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemodialysis. Chronic kidney disease (CKD)

Interventions

Intervention 1: Intervention group: 50000 IU vitamin D every 2 weeks (Zahravi, Tabriz, Iran), for 12 weeks orally. Intervention 2: Control group: Placebo (Barij Essence, Kashan, Iran) every 2 weeks, f

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients diabetic hemodialysis Individuals aged 18 to 80 years old

Exclusion criteria

Exclusion criteria: Taking vitamin D, antioxidant, anti-inflammatory and immunosuppressive drugs during three months before intervention

Design outcomes

Primary

Measure	Time frame
Expressed levels of PPAR-? gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: RT-PCR.	—

Secondary

Measure	Time frame
Expressed levels of LDLR gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: RT-PCR.;Expressed levels of GLUT4 gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: RT-PCR.;Expressed levels of IRS1 gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: RT-PCR.;Expressed levels of IRS2 gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: RT-PCR.;Expressed levels of LP (a) gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: RT-PCR.;Expressed levels of PDK1 gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: RT-PCR.;Expressed levels of PI3K gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: RT-PCR.;Expressed levels of PKC gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: RT-PCR.	—

Measure

Time frame

Expressed levels of LDLR gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: RT-PCR.;Expressed levels of GLUT4 gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: RT-PCR.;Expressed levels of IRS1 gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: RT-PCR.;Expressed levels of IRS2 gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: RT-PCR.;Expressed levels of LP (a) gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: RT-PCR.;Expressed levels of PDK1 gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: RT-PCR.;Expressed levels of PI3K gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: RT-PCR.;Expressed levels of PKC gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: RT-PCR.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_z@kaums.ac.ir+98 31 5562 1158

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026